Docivyx (Docetaxel) Patent Expiration, LOE Window & CMS Spending

Docivyx (Docetaxel) by Avyxa Holdings: FDA Orange Book LOE 2036-03-14, 0 AB generics, $2.3M 2024 CMS Part D & Medicaid spend, and $7,920 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAvyxa Holdings
FDA Application & PathwayN215813 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2036-03-14
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2.3M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$2.3M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($7,920 intro WAC)